105 related articles for article (PubMed ID: 16960766)
1. [How are quality-adjusted life years defined in German studies?].
Schwappach DL; Boluarte TA
Dtsch Med Wochenschr; 2006 Sep; 131(37):2004-9. PubMed ID: 16960766
[TBL] [Abstract][Full Text] [Related]
2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
3. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
4. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.
Richardson G; Manca A
Health Econ; 2004 Dec; 13(12):1203-10. PubMed ID: 15386669
[TBL] [Abstract][Full Text] [Related]
5. Economic value of out-of-hospital emergency care: a structured literature review.
Lerner EB; Maio RF; Garrison HG; Spaite DW; Nichol G
Ann Emerg Med; 2006 Jun; 47(6):515-24. PubMed ID: 16713777
[TBL] [Abstract][Full Text] [Related]
6. Not all "quality-adjusted life years" are equal.
Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
[TBL] [Abstract][Full Text] [Related]
7. [Cost-utility analysis; uncertainties restrict applicability].
de Neeling JN
Ned Tijdschr Geneeskd; 2004 May; 148(22):1106-10. PubMed ID: 15198066
[TBL] [Abstract][Full Text] [Related]
8. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
9. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
10. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
Brennan A; Ara R; Sterz R; Matiba B; Bergemann R
Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345
[TBL] [Abstract][Full Text] [Related]
11. Preference-based outcome measures in cost-utility analyses. A 20-year overview.
Greenberg D; Pliskin JS
Int J Technol Assess Health Care; 2002; 18(3):461-6. PubMed ID: 12391940
[TBL] [Abstract][Full Text] [Related]
12. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life after stroke: review of the literature and implications for future research.
Tseng MC; Lin HJ
Acta Neurol Taiwan; 2007 Mar; 16(1):7-12. PubMed ID: 17486727
[TBL] [Abstract][Full Text] [Related]
14. Cost utility for penetrating keratoplasty in patients with poor binocular vision.
Hirneiss C; Neubauer AS; Niedermeier A; Messmer EM; Ulbig M; Kampik A
Ophthalmology; 2006 Dec; 113(12):2176-80. PubMed ID: 16996598
[TBL] [Abstract][Full Text] [Related]
15. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
Roe RH; Lass JH; Brown GC; Brown MM
Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
[TBL] [Abstract][Full Text] [Related]
17. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
18. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
19. Global cost-effectiveness of cataract surgery.
Lansingh VC; Carter MJ; Martens M
Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
[TBL] [Abstract][Full Text] [Related]
20. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio.
van Baal PH; Feenstra TL; Hoogenveen RT; de Wit GA; Brouwer WB
Health Econ; 2007 Apr; 16(4):421-33. PubMed ID: 17039573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
